PSY69 Consequences Of Patient Access Restrictions To Branded Oxycodone Hydrochloride Controlled-Release On Health Care Utilization And CostsA Case-Control Study Of United States Health Plans  by Ben-Joseph, R et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A235
BAckground:: Worldwide the judiciary branch has been an active player in pub-
lic health policies, especially regarding drugs. In Brazil, this is a huge concern. 
This abstract presents an evaluation of the judicial response to cases regarding 
three biological drugs: etanercept (enbrel), infliximab (remicade) and adalimumab 
(humira), all TNF inhibitor agents for the treatment of patients with autoimmune 
diseases. oBjectives: To identify the prevalence of scientifically grounded judi-
cial decisions and the knowledge of Brazilian judges regarding clinical protocols, 
evidence-based medicine and health technology assessment. Methods: Electronic 
databases of the Supreme Court (STF), the Superior Court of Justice (STJ) and all 
Federal Regional Courts (TRFs) were searched using the keywords “etanercept” 
(enbrel), “infliximab” (remicade) and “adalimumab” (humira). results: 102 judicial 
decisions were found: 6 collegial judgments (6%) and 96 monocratic decisions (94%). 
Of these, 29 were excluded due to procedural reasons (28%) and 73 met the eligibility 
criteria (72%). Of those 73, 69 decisions (95%) determined that government have to 
supply the medications. Only 2 decisions (2.5%) considered it improper to supply the 
drug due to a lack of evidence regarding its effectiveness. Additionally, 2 decisions 
(2.5%) determined the need for forensic expertise. Out of the 73 decisions examined, 
65 did not rely on scientific evidence. Another 2 referred to evidence-based medi-
cine, without, however, taking it as a plea for the decision-making process. Only 2 
decisions considered evidence as a basis for decision-making. On the other hand, 
just 4 decisions referred to expert medical opinions. conclusions: The judiciary 
branch does not rely on scientific evidence or health technology assessment as a 
tool to the decision-making process. In order to preserve the right to health and the 
public health system´s sustainability, it is necessary to employ medical evidence 
methods in judicial decisions.
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oBjectives: The American College of Medical Genetics (ACMG) recommended 
expanding and standardizing the group of rare conditions in US newborn screening 
(NBS) in 2006. This research examines the correspondence between ACMG recom-
mendations and state implementation and contrasts this with Europe. Methods: 
We collected historical data on conditions screened in state programs. We defined 
conditions as Recommended (R list) based on whether a condition was in ACMG’s 
Core of 29 conditions plus 25 secondary conditions groupings. We then assessed 
each state’s (plus D.C.) correspondence with ACMG recommendations. We also 
collected data from Europe. results: The mathematical union of all conditions 
screened in the 51 US geographies is 74. In 2005, prior to the expansion, geographies 
varied in NBS screening from a low of 4 conditions to a high of 46 (mean= 24). This 
represented a significant increase over that from 10 years earlier (mean= 5; range= 
0-8). Currently, the mean number of conditions screened is 48 (range 31-64). Twenty 
geographies screen for at least 50 of the 54 ACMG recommendations. Only 3 geog-
raphies screen for the complete R list; these 3 and 22 others screen for additional 
conditions not on the R list. All US geographies screen for more than 20 conditions. 
In contrast, recent European data indicate a range from 1 to 29 conditions among 
37 geographies reporting data (mean= 8), with only 6 geographies reporting 20 or 
more. conclusions: The expansion of NBS in the US has been a success in terms 
of correspondence with ACMG recommendations with 20 of the 51 US geographies 
adhering to at least 50 of the original 54 ACMG recommendations. The contrast with 
European geographies raises questions about the expansion. Whether it is a positive 
development depends on its costs and health implications.
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oBjectives: This study evaluated the impact of increasing patient access restric-
tions to branded oxycodone hydrochloride controlled-release tablets (OXY) on phy-
sician office visits, pharmacy utilization and costs. Methods: This retrospective 
case-control study of IMS’s medical/pharmacy claims and Formulary Focus database 
analyzed adult patients with ≥ 1 extended-release and long-acting opioid Rx claim 
indexed between 1/1/2009 and 12/31/2011. Patients with ≥ 6 month’s observation in 
pre-restriction or post-restriction periods were analyzed. Cases included patients 
in commercial or Medicare plans imposing access restrictions (tier change [TC] or 
prior-authorization [PA]), thus forming four groups: commercial PA (Com-PA), com-
mercial TC (Com-TC), Medicare PA (MC-PA) and Medicare TC (MC-TC). Controls were 
selected from plans without access restrictions and were matched based on demo-
graphics, clinical characteristics, payer type and index quarter. Pharmacy and office 
visit utilization and costs were measured for 6 months following each patient’s 
index date, comparing the pre- to post-restriction period within each study group. 
Bootstrapping t-test and generalized linear models were utilized to test the differ-
ences in resource utilization and costs. results: The study groups were approxi-
mately 55 years old and 60% female. A significant increase in 6-month office visits 
was observed from the pre to the post-restriction period in plans imposing access 
restrictions: COM-PA (2.13, p< 0.001), COM-TC (1.29, p= 0.017), MC-PA (0.81, p= 0.021), 
MC-TC (1.00, p< 0.001). Total (medical+pharmacy) mean pre to post-restriction cost 
increases of $1,019 (p< 0.001), $433 (p= 0.076), $684 (p< 0.001) and $348 (p< 0.001) were 
also observed in the access restricted groups, respectively. No significant change in 
office visits or costs were observed in the COM-TC, MC-PA or MC-TC control groups, 
however, an increase was observed in the control group matched to the COM-PA 
group for office visits (2.01, p= 0.001) and total costs ($969, p< 0.001). conclusions: 
oBjectives: To examine the association between continuity of care and risk of 
potentially inappropriate concomitant medication (PICM) in continuous non-
steroidal anti-inflammatory drug (NSAID) users. Methods: Longitudinal Health 
Insurance Database 2005 (LHID2005) which contains one million of randomly sam-
pled beneficiaries from National Health Insurance (NHI) in Taiwan was used to 
identify continuous NSAID users who were prescribed with NSAID more than 
30 days in 2005. NSAID’s PICM was defined as if there are significant drug-drug 
interactions (DDI) event based on Drug Interaction Facts. Continuity of care (COC) 
index was used to measure the degree of continuous care for these NSAID users. 
Multiple logistic regression analysis was then applied to estimate the associa-
tion between continuity of care and PICM. results: There were 52,010(5.2% of 
LHID2005) beneficiaries using NSAID more than 30 days in 2005, and 20.2% of 
continuous NSAID users had PICM. Of which, Beta blocking agents was the most 
frequently prescribed and accounted for 8.79% of total PICM. Compared with lower 
level of COC, the odds ratios of PICM were 0.89(95% confidence interval 0.84-0.94) 
and 0.76(95% confidence interval 0.71-0.80) respectively for medium and high 
levels of continuity of care when personal, physician and institutional character-
istics were controlled in logistic regression. conclusions: PICM was common 
for continuous NSAID users in Taiwan, especially in those who had lower level of 
COC. While the consequence of PICM has to be investigated further, health policy 
directed to improvethe continuity of caremay reduce the risk of drug interactions 
in NSAID users.
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oBjectives: CLL is an indolent incurable lymphoma with a widely variable disease 
course. Its treatment is therefore quite heterogeneous. The goal of this project was 
to evaluate the real-world use of individual agents or combination regimens across 
all lines of therapy in CLL during the years 2010-2013 in order to understand the cur-
rent treatment paradigm of CLL. Methods: Treatment records for 110,000 cancer 
patients and over 6.7 million drug administrations were evaluated between August 
2010 and July 2013 at US cancer care facilities participating in a nationwide, commer-
cially available chemotherapy order entry system called IntelliDose®. IntelliDose® 
captures patient demographics, stage, and details of chemotherapy treatment. The 
composition of the 820 oncologists who use IntelliDose® is much like the overall 
population of oncologists in the US, including 54% in private practice and 41% com-
munity hematologist/oncologists. The CLL patients sampled by IntelliDose® were 
projected to a national level for the interpretation of the results. results: The 
average monthly number of CLL patients undergoing any line of treatment was 7,736 
(SD= 565). Of the 3,380 patients receiving first line therapy, the majority of patients 
(n= 810; 24%) were receiving Bendamustine-Rituximab (BR), followed by Fludarabine- 
Cyclophosphamide -Rituximab (FCR) (n= 716; 21%).For relapsed CLL, BR was also the 
most common regimen (18-33% of monthly use), followed by R monotherapy (7- 16% 
of monthly use). Across all lines of therapy, BR is the most common regimen used 
(14-32% monthly use) followed by R alone as the second most common regimen 
(18-25% of monthly use). conclusions: Rituximab is the most frequently used 
agent either as a single agent or in combination, in all lines of CLL treatment in the 
US. Single agent Rituximab is commonly used in CLL therapy in 2nd line and above, 
despite low reported response rates in the literature.
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oBjectives: There are currently 68 orphan drugs with European marketing authori-
zation with orphan designation and 75 orphan drugs without prior orphan des-
ignation in EU. Current Health technology appraisal recommendations in Slovak 
Republic do not include any specific guidelines for reimbursement of orphan drugs 
(OD). Orphan drug reimbursement decisions are made on case-to-case basis and no 
clear rules are currently present. We evaluated market uptake of selected 90 orphan 
drugs and compared it to total market evolution from 2005 to 2012. Methods: Our 
analysis include volume and sales evolution of 90 orphan drugs in Slovak Republic 
from 2005 to 2012 using Health database and publicly available data. results: 
Results show that cumulative 8-years expenditure for selected list of ODs is over 
1,1 billion EUR. The peak sale was reached in 2012 and that sale accounted for 
18,6% from total pharmaceutical spending in 2012. The highest sales growth was 
in 2006 with 33,4% compared to previous year. Until 2009, we have seen strong 
double-digit growth following by still high single digit growth in 2010 (6,1%) and 
2012 (7,6%). Total expenditure represented 10,7%, 12,4%, 12,8%, 13,5%, 14,7%, 15,2%, 
16,5% and 18,6% of total medicine expenditure from 2005 to 2012 in SK, respectively. 
The highest expenditure burden lies on one ATC category: L- antineoplastic and 
immunomodulating agents with 57% share. conclusions: The uptake of orphan 
drugs is according to EU standards very high, but it must be noted that many ODs 
are locally off-patent and generics expand the market. Secondly, we included into 
our selection ODs with and without prior orphan designation. Nevertheless, it is 
important to make more detailed analysis and advocate for prudent reimbursement 
rules for orphan drugs, mainly from local HTA perspective.
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focused around more scrutiny in the reimbursement assessment of orphan 
drugs. conclusions: All twenty stakeholders gave recommendations about a 
stronger European cooperation for the value assessment of orphan drugs, with 
eleven stakeholders suggesting a European reimbursement system for orphan 
drugs.
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oBjectives: Reimbursement processes have been implemented to inform which 
therapies should be funded in light of scarce health care resources. However, the 
applicability of standard processes to drugs for rare diseases is heavily debated. As 
a result of the small patient populations affected by rare diseases, coupled with a 
limited understanding of the natural history of these conditions and the high cost of 
these treatments, it is argued that drugs for rare diseases may not meet the eviden-
tiary standards routinely applied when making resource allocation decisions. This 
study identified current reimbursement processes for prescription pharmaceuticals 
both within Canada and internationally, with the objective of assessing how drugs 
for rare diseases are considered within existing processes. Methods: Using the 
G20 countries as a sampling frame, a review of published and grey literature was 
conducted to identify the reimbursement processes used in 28 countries, and in 
Canadian provinces/territories. A search for peer-reviewed publications was con-
ducted using Medline, Scopus, CINHAL, EconLit and PsychInfo. The grey literature 
search included websites of health technology assessment agencies and govern-
ment agencies. results: Drugs for rare diseases are considering uniquely for reim-
bursement within three Canadian provinces and seven countries. Reimbursement 
frameworks focused specifically on the reimbursement of drugs for rare diseases 
are limited. In some jurisdictions, drugs for rare diseases are considered uniquely 
within the established decision-making process for drugs. Varying decision criteria 
are applied within the identified processes for the reimbursement of drugs for rare 
diseases. conclusions: This review identifies approaches for making resource 
allocation decisions for drugs; explicitly considering funding decisions related to 
drugs for rare diseases. An understanding of these frameworks and the decision 
criteria applied when making resource allocation decisions may help inform the 
development of more standardized approaches for the reimbursement of drugs 
for rare diseases.
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oBjectives: To identify research studies that examine the economic and/or 
humanistic burden of R/R iNHL, and identify evidentiary gaps which could be 
informed by future research. Methods: iNHL refers to a group of largely incur-
able slow-growing lymphomas that run a relapsing course after therapy, and 
can lead ultimately to life-threatening complications. Although many thera-
pies are available, patients eventually relapse and become refractory to existing 
therapies. As such, additional treatment options with improved response rate, 
durability of response and more manageable toxicity are needed to treat patients 
with R/R iNHL. A structured literature search was performed to assess the eco-
nomic and patient burden of iNHL. English-language articles published since 
2009 were systematically reviewed in PubMed, EMBASE and Cochrane databases. 
Additionally, searches from global HTA organizations and conference abstracts 
were performed. Research was considered relevant to the economic and human-
istic burden of iNHL based on reported outcomes such as resource utilization, 
costs, or relevant patient-reported outcomes associated with relapsed/refractory 
iNHL. results: Few cost-of-illness studies or HTAs address iNHL. Evidence was 
limited to hospital-based direct treatment costs, omitting societal and indirect 
costs of the disease. Multiple cost-effectiveness analyses were identified focusing 
on Rituximab; however, few studies evaluated the cost-effectiveness of alterna-
tive 2nd or 3rdline therapies in the case of R/R iNHL. The majority of identified 
patient reported outcomes (PRO) research exists as conference abstracts. No stud-
ies were identified that examine PRO in a R/R iNHL population. conclusions: 
The economic and humanistic burden of R/R iNHL has not been widely reported 
in the literature. Areas of future research may include evaluating both direct 
and indirect costs in R/R iNHL. PROs are not well understood in iNHL, and future 
research should focus on QoL and related factors that may help evaluate any 
trade-off between progression-free survival and the severity/duration of adverse 
events.
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oBjectives: In context of Health Technology Assessment (HTA) decision frame-
work, some countries (e.g. Germany) have a special regulation for orphan drugs 
(OD), while others (e.g. France) don’t. The aim of the study was to compare the 
HTA decisions, prices and reimbursements for the OD that have been evaluated in 
France and Germany. Methods: We selected OD assessed under AMNOG law in 
Germany and reviewed HTA assessments from the Transparency Committee (TC) 
for France and from IGWiG/G-BA for Germany, and extracted prices and reimburse-
These analyses suggest that OXY access restrictions such as PA and TC did not 
result in cost savings.
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oBjectives: In 2006, the American College of Medical Genetics (ACMG) recom-
mended a significantly expanded group of rare conditions for state-based US 
NBS programs. Initial efforts to explore the implications of this expansion used 
national incidence data applied to the states due to an inability to gather current 
state-specific numbers. Older state-specific numbers were later identified. This 
research assesses the error associated with estimating consequences of these 
programs by using national vs. state-specific incidence estimates. Methods: We 
collected data on national disease incidence and state-specific numbers of births 
(2011), state-specific disease cases (2003 and 2006) and number of required NBS 
tests/birth and reported fees. We developed two estimates of cases: 1) expected 
cases by applying national incidence to current state births and 2) cases identified 
using state-specific actual observations (averaged over the 2 years and applied 
to current number of births). We also calculated the cost per expected identified 
case using both methods of estimating cases. results: The differences in num-
bers based on state actuals vs. expected cases calculated from national incidence 
estimates was expressed as a percentage of the actuals. For CH this ranged from 
-71% to + 200% (mean= -33%; 46 were negative; 2 were positive; 3 unchanged) and 
in CAH from -67% to + 500% (mean= +70%; 9 were negative; 22 were positive; 7 
unchanged and 13 missing or undefined due to no cases being in the denominator 
of the calculation). Similar differences were observed in calculations of cost per 
identified cases. conclusions: Sampling variation and the association with 
ethnicity and other differences by state demographics implied added variation 
in state actuals compared to national incidence used in predictions. The one-
sided error observed in the CH calculations leads us to question the accuracy of 
the national incidence figure. Application of national incidence to state-specific 
situations should proceed with caution.
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BAckground:: Obesity can be understood as a problem resulting from the imbal-
ance between the intake and the individual caloric expenditure, which has sparked 
concern among researchers and policymakers in public health. The alert comes 
up with the fast growth in the prevalence of obesity in adults and children in 
Brazil. oBjectives: In this context, the challenge of this essay is to analyze the 
major changes in BMI between 2002 and 2009 and to estimate the relationship 
between food prices and obesity, in order to check the effect of food prices on BMI 
in Brazil. Methods: To assess the changes in BMI over time, first of all, we analyze 
its distribution using the relative distribution method proposed by Handcock and 
Morris (1998). Then, recentered influence function (RIF) regressions were applied 
to decompose the changes in the BMI distribution into composition and struc-
ture effects and identify the specific contribution of food prices. The empirical 
estimates needed are based on micro-data from household budget survey in 
two points of time: 2002-2003 and 2008-2009 accomplished by the Brazilian 
Institute of geography (IBGE). Were considered only the information regarding 
the adult population aged less than 20 years. results: The main changes in 
BMI distribution showed that the density has moved to the right over the time 
and there were increases in the right hand tail. Despite the small effect, the RIF 
results show that the prices variations over the period contributed to change BMI. 
If prices had not changed, the median BMI would be 0.22 higher. The increases in 
the prices of meat, ssb and fruits and vegetables showed the greatest mean effects 
on BMI, especially to upper quantiles of the distribution. There are also evidences 
that income and age contributed to rise BMI, while education is associated to a 
lowering effect.
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oBjectives: In 2000 the Orphan Drug Act was designed to supported drug devel-
opment for rare disease in Europe. Now thirteen years after the Act was passed, 
orphan drug development has immensely increased and health care systems 
are challenged to find more appropriate assessment mechanism for the reim-
bursement of orphan drugs. Public awareness has lately been raised by major 
discussions about the discontinuation of reimbursement for several orphan drugs. 
By conducting qualitative interviews this article aims to identify the view of dif-
ferent stakeholders about recent and future changes within the reimbursement 
assessment and its evidence requirements for orphan drugs. Methods: Twenty 
semi-structured interviews were conducted with relevant stakeholders from the 
orphan drug community. Interviewees were scientific experts, reimbursement 
agencies, industry and patient organizations from five European countries. The 
interviews were analyzed with the framework analysis technique. results: 
All twenty stakeholders have reported about recent or future changes in their 
national reimbursement practice for orphan drugs. The most emerging theme 
